Serial Non-contrast Non-gated T2w MRI Datasets of Patient-derived Xenograft Cancer Models for Development of Tissue Characterization Algorithms

<p>This collection contains serial non-contrast non-gated T2w MRI of 18 patient derived xenograft cancer models. 175 mice were imaged at multiple time points (514 total studies) for researchers to develop algorithms using neural networks, and classification techniques to improve tissue characterization (morphological changes) for the improvement in patient care through advances in precision medicine.  </p><p>Characterization of tissue using non-invasive in vivo imaging techniques is used for detection and measurement of disease burden in oncology. Researchers have developed numerous algorithms, such as neural networks, and classification techniques to improve the characterization (morphological changes) of tissue. Unfortunately, to obtain statistical significance, large datasets are a requirement in this research endeavor due to tumor heterogeneity within the same histologic classification. Pre-clinical patient derived xenograft animal models can be a significant resource by providing collections with a more homogenous tumor genome across the collection with companion genomic and pathologic characterization available (<a href="https://pdmr.cancer.gov/">https://pdmr.cancer.gov/</a>), allowing determination of the variability of imaging characteristics.</p><p>This dataset of a patient derived xenograft model (below table) can be used for training algorithms for evaluating variations in tissue texture with respect to tumor growth and cancer model.</p><h3>PDX Model Characterizations and Biweekly imaging sessions </h3><div><table><tbody><tr><td> </td><td> </td><td><p><strong> </strong></p></td><td><p><strong> </strong></p></td><td colspan="3"><p><strong>Characterization</strong></p></td><td><p>1</p></td><td><p>2</p></td><td><p>3</p></td><td><p>4</p></td><td><p>5</p></td><td><p>6</p></td><td><p>7</p></td><td><p>8</p></td></tr><tr><td><p><strong>Model  ID</strong></p></td><td><p><strong>CTEP SDC Description</strong></p></td><td><p><strong>Disease Body Location</strong></p></td><td><p><strong>  Biopsy site</strong></p></td><td><p>Implant Date</p></td><td><p>Passage</p></td><td><p>Gender</p></td><td colspan="8"><p># Mice imaged per biweekly imaging session</p></td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:3466,5509">144126-210-T</a></p></td><td><p>Neuroendocrine cancer, NOS</p></td><td><p>Endocrine and Neuroendocrine</p></td><td><p>* Liver</p></td><td><p>2/14/2020</p></td><td><p>4</p></td><td><p>M</p></td><td><p>8</p></td><td><p>8</p></td><td><p>5</p></td><td><p>5</p></td><td><p>5</p></td><td><p>5</p></td><td> </td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:1644,2836">146476-266-R</a></p></td><td><p>Urothelial/bladder cancer, NOS</p></td><td><p>Genitourinary</p></td><td><p>Bladder</p></td><td><p>2/3/2020</p></td><td><p>4</p></td><td><p>M</p></td><td><p>17</p></td><td><p>16</p></td><td><p>13</p></td><td><p>10</p></td><td><p>11</p></td><td><p>4</p></td><td><p>4</p></td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:445,700">165739-295-R</a></p></td><td><p>Adenocarcinoma-pancreas</p></td><td><p>Digestive/Gastrointestinal</p></td><td><p>Pancreas</p></td><td><p>5/4/2018</p></td><td><p>2</p></td><td><p>M</p></td><td><p>10</p></td><td><p>10</p></td><td><p>1</p></td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:186,202">172845-121-T</a></p></td><td><p>Adenocarcinoma-colon</p></td><td><p>Digestive/Gastrointestinal</p></td><td><p>* Liver</p></td><td><p>10/16/2020</p></td><td><p>4</p></td><td><p>F</p></td><td><p>20</p></td><td><p>20</p></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:186,213">172845-142-T</a></p></td><td><p>Adenocarcinoma-colon</p></td><td><p>Digestive/Gastrointestinal</p></td><td><p>* Liver</p></td><td><p>8/24/2018</p></td><td><p>3</p></td><td><p>F</p></td><td><p>15</p></td><td><p>13</p></td><td><p>8</p></td><td><p>3</p></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:856,1664">287954-098-R</a></p></td><td><p>Ewing sarcoma/Peripheral PNET</p></td><td><p>Musculoskeletal</p></td><td><p>* Pelvis</p></td><td><p>3/18/2021</p></td><td><p>6</p></td><td><p>M</p></td><td><p>10</p></td><td><p>8</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td> </td><td> </td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:721,1330">466636-057-R</a></p></td><td><p>Adenocarcinoma-pancreas</p></td><td><p>Digestive/Gastrointestinal</p></td><td><p>Pancreas</p></td><td><p>12/15/2017</p></td><td><p>N/A</p></td><td><p>M</p></td><td><p>5</p></td><td><p>4</p></td><td><p>2</p></td><td><p>1</p></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:3228,5141">521955-158-R4</a></p></td><td><p>Adenocarcinoma-pancreas</p></td><td><p>Digestive/Gastrointestinal</p></td><td><p>* Tumor in colonic fat</p></td><td><p>9/30/2021</p></td><td><p>4</p></td><td><p>F</p></td><td><p>10</p></td><td><p>10</p></td><td><p>10</p></td><td><p>8</p></td><td><p>5</p></td><td><p>1</p></td><td><p>1</p></td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:3228,5143">521955-158-R6</a></p></td><td><p>Adenocarcinoma-pancreas</p></td><td><p>Digestive/Gastrointestinal</p></td><td><p>* Myometrium</p></td><td><p>3/27/2018</p></td><td><p>N/A</p></td><td><p>F</p></td><td><p>7</p></td><td><p>7</p></td><td><p>4</p></td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:875,1715">625472-104-R </a> </p></td><td><p>Adenocarcinoma-colon</p></td><td><p>Digestive/Gastrointestinal</p></td><td><p>* Shoulder</p></td><td><p>8/27/2019</p></td><td><p>2</p></td><td><p>F</p></td><td><p>9</p></td><td><p>1</p></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:1106,2151">695669-166-R</a></p></td><td><p>Melanoma</p></td><td><p>Skin</p></td><td><p>Arm</p></td><td><p>4/16/2021</p></td><td><p>3</p></td><td><p>M</p></td><td><p>7</p></td><td><p>8</p></td><td><p>8</p></td><td><p>6</p></td><td><p>4</p></td><td><p>4</p></td><td><p>2</p></td><td><p>2</p></td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:1516,2696">698357-238-R</a></p></td><td><p>Osteosarcoma</p></td><td><p>Musculoskeletal</p></td><td><p>Scapula</p></td><td><p>3/5/2021</p></td><td><p>6</p></td><td><p>F</p></td><td><p>7</p></td><td><p>4</p></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:389,590">765638-272-R</a></p></td><td><p>Squamous cell lung carcinoma</p></td><td><p>Respiratory/Thoracic</p></td><td><p>* Liver</p></td><td><p>3/26/2021</p></td><td><p>4</p></td><td><p>F</p></td><td><p>7</p></td><td><p>8</p></td><td><p>5</p></td><td><p>3</p></td><td><p>1</p></td><td> </td><td> </td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:944,1875">779769-127-R</a></p></td><td><p>Adenocarcinoma-rectum</p></td><td><p>Digestive/Gastrointestinal</p></td><td><p>Rectum</p></td><td><p>2/19/2020</p></td><td><p>5</p></td><td><p>F</p></td><td><p>5</p></td><td><p>5</p></td><td><p>5</p></td><td><p>5</p></td><td><p>3</p></td><td><p>4</p></td><td> </td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:236,302">833975-119-R</a></p></td><td><p>Adenocarcinoma-pancreas</p></td><td><p>Digestive/Gastrointestinal</p></td><td><p>Pancreas</p></td><td><p>10/23/2019</p></td><td><p>2</p></td><td><p>F</p></td><td><p>12</p></td><td><p>12</p></td><td><p>11</p></td><td><p>7</p></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:951,1913">894883-131-R</a></p></td><td><p>Squamous cell carcinoma-anus</p></td><td><p>Digestive/Gastrointestinal</p></td><td><p>Buttock</p></td><td><p>2/25/2022</p></td><td><p>5</p></td><td><p>F</p></td><td><p>6</p></td><td><p>6</p></td><td><p>6</p></td><td><p>1</p></td><td><p>1</p></td><td> </td><td> </td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:3301,5260">997537-175-T</a></p></td><td><p>Adenocarcinoma-colon</p></td><td><p>Digestive/Gastrointestinal</p></td><td><p>* Liver</p></td><td><p>10/25/2018</p></td><td><p>3</p></td><td><p>M</p></td><td><p>9</p></td><td><p>2</p></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><p><a href="https://pdmdb.cancer.gov/web/apex/f?p=101:4:::NO:4:P4_PATIENTSEQNBR,P4_SPECIMENSEQNBR:12,12">BL0382-F1232</a></p></td><td><p>Urothelial/bladder cancer, NOS</p></td><td><p>Genitourinary</p></td><td><p>Bladder</p></td><td><p>5/20/2020</p></td><td><p>4</p></td><td><p>F</p></td><td><p>9</p></td><td><p>6</p></td><td><p>4</p></td><td><p>1</p></td><td><p>1</p></td><td> </td><td> </td><td> </td></tr></tbody></table></div><p>Note: Biopsy sites labeled with an (*) were obtained from a metastatic site.  All other biopsy sites were at the primary tumor site.</p><p>In this study we performed non-contrast non-gated T2w MRI (SOP50101_MRI), initiated 2 weeks post implantation, and continued biweekly imaging sessions until their tumors reached a size requiring humane termination (ACUC guidance > 2 cm in any linear dimension by caliper or MRI measurement) or their clinical status required euthanasia. Fragments (2x2x2 mm<sup>3</sup>) from the NCI/DCTD PDMR repository were implanted into 5-10 donor mice (NOD.Cg-Prkdc<sup>scid</sup>Il2rg<sup>tm1Wjl</sup>/SzJ (NSG)). When tumors reached enrollment criteria (100 – 300 mm<sup>3</sup>), tumors were excised, cut into 2x2x2 mm<sup>3</sup> fragments and implanted with Matrigel (per PDMR SOP50101_Tumor Implantation) into NSG study mice. The multi-mouse non-gated DICOM dataset was split according to the <a href="https://doi.org/10.3390/tomography7010001">method published in Tomography</a> and retained their individual mouse DICOM header information.  Structured Reports (SR) were added to the dataset to include fragment implant date, CTEP description, mouse strain (NSG) and model.</p><p>The genomic and pathologic characteristics of these models, which is available from the National Cancer Institute Patient-Derived Models Repository (<a href="https://pdmr.cancer.gov/">https://pdmr.cancer.gov/</a>), can be used in conjunction with this publicly available dataset to guide the development of algorithms for enhanced characterization of tissue for precision medicine.</p>

本数据集包含18个患者来源异种移植癌症模型的序列非对比非门控T2w MRI图像。为了研究人员开发使用神经网络和分类技术来改善组织特征（形态学变化）的算法，以提高精准医学的病人护理水平，对175只小鼠进行了多次时间点的成像（总计514项研究）。在肿瘤异质性导致同一病理学分类内数据集需要大量样本以获得统计学意义的情况下，非侵入性体内成像技术在肿瘤学中用于检测和测量疾病负担。研究人员已开发了多种算法，如神经网络和分类技术，以改善组织的特征（形态学变化）。遗憾的是，由于肿瘤异质性，为了获得统计学上的显著性，需要大量的数据集。临床前患者来源的异种移植动物模型可以作为一种重要的资源，通过提供具有更同质肿瘤基因组的数据集，并伴随基因组学和病理学特征（见<a href="https://pdmr.cancer.gov/">https://pdmr.cancer.gov/</a>），允许确定成像特征的可变性。本患者来源异种移植模型数据集（下表）可用于训练算法，以评估组织纹理在肿瘤生长和癌症模型中的变化。